These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15981557)

  • 1. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece.
    Maniadakis N; Kaitelidou D; Siskou O; Spinthouri M; Liaropoulos L; Fragoulakis B; Hatzikou M; Alexopoulosi D
    Hellenic J Cardiol; 2005; 46(3):212-21. PubMed ID: 15981557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
    Barradell LB; Goa KL
    Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of thrombolytics: a simplified model.
    Apikoğlu Rabuş S; Izzettin FV; Sancar M; Rabuş MB; Kirma C; Yakut C
    Pharm World Sci; 2005 Jun; 27(3):243-8. PubMed ID: 16096895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 5. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of reteplase with alteplase for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
    N Engl J Med; 1997 Oct; 337(16):1118-23. PubMed ID: 9340503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
    Pelc A; Dardenne J; Frelon JH; Hanania G
    Pharmacoeconomics; 1997 Jun; 11(6):595-605. PubMed ID: 10173031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
    Grunwald MR; Hofmann LV
    J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
    Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG
    Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
    Wooster MB; Luzier AB
    Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.
    Boudreau DM; Guzauskas G; Villa KF; Fagan SC; Veenstra DL
    Ann Emerg Med; 2013 Jan; 61(1):46-55. PubMed ID: 22633340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke.
    Joo H; Wang G; George MG
    Am J Prev Med; 2017 Dec; 53(6S2):S205-S212. PubMed ID: 29153122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA.
    Seyedroudbari A; Kessler ER; Mooss AN; Wundeman RL; Bala M; Hilleman DE
    J Thromb Thrombolysis; 2000 Apr; 9(3):303-8. PubMed ID: 10728031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of thrombolysis administered by paramedics.
    Scuffham PA; Tippett V
    Curr Med Res Opin; 2008 Jul; 24(7):2045-58. PubMed ID: 18544187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction.
    Tsikouris JP; Tsikouris AP
    Pharmacotherapy; 2001 Feb; 21(2):207-17. PubMed ID: 11213858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction.
    Amsterdam EA
    Pharmacotherapy; 1996; 16(5 Pt 2):137S-140S. PubMed ID: 8888101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.